MedPath

CHA VACCINE INSTITUTE CO.,LTD.

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:4
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (80.0%)
Phase 2
1 (20.0%)

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine

Phase 1
Completed
Conditions
Hepatitis B
Vaccine-Preventable Diseases
First Posted Date
2023-11-28
Last Posted Date
2024-03-25
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
Target Recruit Count
30
Registration Number
NCT06147895
Locations
🇰🇷

CHA University Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Phase 1
Recruiting
Conditions
Vaccine-Preventable Diseases
Herpes Zoster
Interventions
First Posted Date
2023-11-18
Last Posted Date
2024-11-19
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
Target Recruit Count
32
Registration Number
NCT06137755
Locations
🇰🇷

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of

🇰🇷

Bundang CHA General Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine

Phase 2
Completed
Conditions
Hepatitis B, Chronic
First Posted Date
2020-02-28
Last Posted Date
2024-02-13
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
Target Recruit Count
134
Registration Number
NCT04289987
Locations
🇰🇷

Chung-ang University Hospital, Seoul, Dongjak-gu, Korea, Republic of

🇰🇷

The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of

and more 6 locations

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

Phase 1
Completed
Conditions
Hepatitis B, Chronic
First Posted Date
2016-02-29
Last Posted Date
2023-11-18
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
Target Recruit Count
53
Registration Number
NCT02693652
Locations
🇰🇷

Bundang CHA General Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine

Phase 1
Completed
Conditions
Healthy
First Posted Date
2016-02-25
Last Posted Date
2023-11-18
Lead Sponsor
CHA Vaccine Institute Co., Ltd.
Target Recruit Count
75
Registration Number
NCT02692170

News

No news found
© Copyright 2025. All Rights Reserved by MedPath